Literature DB >> 10805975

Mycobacterium tuberculosis inhibits MHC class II antigen processing in murine bone marrow macrophages.

E H Noss1, C V Harding, W H Boom.   

Abstract

Infection of murine bone-marrow-derived macrophages with viable Mycobacterium tuberculosis (MTB) H37Ra inhibited surface expression of MHC class II (MHC-II) molecules and processing of exogenous antigens for presentation to CD4(+) T hybridoma cells. The inhibition was not dependent on bacterial viability, since it was also produced by exposure to dead bacilli and MTB cytosol preparations, suggesting that it was initiated by a constitutively expressed bacterial component. Northern blot analysis demonstrated that MTB bacilli or cytosol decreased MHC-II mRNA, and immunoprecipitation of biosynthetically labeled molecules confirmed that MHC-II protein synthesis was diminished. Exposure to MTB or MTB cytosol also decreased expression of H2-DM, but H2-DM expression was still sufficient to catalyze conversion of MHC-II to SDS-stable dimers, a measure of MHC-II peptide loading. Thus, infection with MTB decreased both MHC-II and H2-DM expression, but diminished MHC-II synthesis provided the major limitation to antigen processing. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10805975     DOI: 10.1006/cimm.2000.1633

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  66 in total

Review 1.  Tuberculosis: latency and reactivation.

Authors:  J L Flynn; J Chan
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

2.  Interferon-alphabeta mediates partial control of early pulmonary Mycobacterium bovis bacillus Calmette-Guérin infection.

Authors:  John Kuchtey; Scott A Fulton; Scott M Reba; Clifford V Harding; W Henry Boom
Journal:  Immunology       Date:  2006-05       Impact factor: 7.397

3.  Rv2468c, a novel Mycobacterium tuberculosis protein that costimulates human CD4+ T cells through VLA-5.

Authors:  Qing Li; Xuedong Ding; Jeremy J Thomas; Clifford V Harding; Nicole D Pecora; Assem G Ziady; Samuel Shank; W Henry Boom; Christina L Lancioni; Roxana E Rojas
Journal:  J Leukoc Biol       Date:  2011-12-07       Impact factor: 4.962

4.  Antigen display, T-cell activation, and immune evasion during acute and chronic ehrlichiosis.

Authors:  Bisweswar Nandi; Madhumouli Chatterjee; Kathryn Hogle; Maura McLaughlin; Katherine MacNamara; Rachael Racine; Gary M Winslow
Journal:  Infect Immun       Date:  2009-07-27       Impact factor: 3.441

5.  Fate of Mycobacterium tuberculosis within murine dendritic cells.

Authors:  K A Bodnar; N V Serbina; J L Flynn
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

6.  Intracellular expression of Mycobacterium tuberculosis-specific 10-kDa antigen down-regulates macrophage B7.1 expression and nitric oxide release.

Authors:  B Singh; G Singh; V Trajkovic; P Sharma
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

Review 7.  Mycobacterium tuberculosis-specific CD8+ T cells and their role in immunity.

Authors:  Joshua S M Woodworth; Samuel M Behar
Journal:  Crit Rev Immunol       Date:  2006       Impact factor: 2.214

8.  Brucella abortus inhibits major histocompatibility complex class II expression and antigen processing through interleukin-6 secretion via Toll-like receptor 2.

Authors:  Paula Barrionuevo; Juliana Cassataro; M Victoria Delpino; Astrid Zwerdling; Karina A Pasquevich; Clara García Samartino; Jorge C Wallach; Carlos A Fossati; Guillermo H Giambartolomei
Journal:  Infect Immun       Date:  2007-11-05       Impact factor: 3.441

9.  Suboptimal Antigen Presentation Contributes to Virulence of Mycobacterium tuberculosis In Vivo.

Authors:  Patricia S Grace; Joel D Ernst
Journal:  J Immunol       Date:  2015-11-16       Impact factor: 5.422

10.  Mycobacterium tuberculosis-specific CD8+ T cells require perforin to kill target cells and provide protection in vivo.

Authors:  Joshua S Woodworth; Ying Wu; Samuel M Behar
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.